Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Alzheimer’s Med Leqembi Approved in South Korea, Its 4th Market
Eisai said on May 27 that Leqembi (lecanemab) has now received regulatory approval in South Korea for the treatment of adult patients with mild cognitive impairment due to Alzheimer’s disease (AD) or mild AD, collectively called early AD.South Korea became…
To read the full story
Related Article
- Leqembi Now Available in South Korea: Eisai
November 29, 2024
BUSINESS
- Marubeni Pharma Seeks New Growth Drivers to Hit FY2035 Sales Goal
July 10, 2026
- Women Hold Nearly 1/4 of Leadership Roles at Japan’s Listed Pharmas and Wholesalers
July 10, 2026
- Roche PD-L1 Test Approved for Imfinzi in Endometrial Cancer
July 10, 2026
- Alexion CEO Calls Japan “Special” for Rare Disease Drug Development
July 9, 2026
- Towa Seeks Policy Reset on Off-Patent Meds, Says Generic Push Has Run Its Course
July 9, 2026
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…